Health-care shares were fairly mixed in pre-market trade Wednesday.
In health-care stocks news, Gilead Sciences ( GILD ) announced its Phase 2 study evaluating simtuzumab in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer failed to meet its primary endpoint of progression-free survival.
Shares of GILD are up $0.73, or 0.70%, at $105.49 in pre-market trading within a 52-week range of $58.81 - $110.64.
And, shareholders of Salix Pharmaceuticals ( SLXP ), a specialty pharmaceutical company, said they want the company to retreat from its proposed acquisition of Cosmo Pharmaceuticals, Reuters reported late Tuesday.
Shares are up 0.46% at $149.40 in the after hours session, with a 52-week range of $65.38 - $162.38.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.